Inspire Medical Systems Inc

Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inspire Medical Systems achieves first profitable quarter, eyes international growth

Inspire Medical Systems reported a strong performance in Q4 2022, achieving its first profitable quarter and significant revenue growth. The company's focus on enhancing patient outcomes, expanding internationally, and optimizing operational efficiency positions it for continued success.
While challenges with the supply chain were addressed, the company needs to remain vigilant in managing disruptions and addressing analyst concerns to ensure sustained growth. Opportunities in product demand, market expansion, and operational enhancements offer avenues for further development.
Overall, Inspire Medical Systems' strategic initiatives, strong financial performance, and commitment to innovation indicate a positive outlook for future growth and market expansion. The company's focus on driving utilization, improving patient outcomes, and maintaining operational efficiency bodes well for its long-term success.

Inspire Medical Systems Inc reports stellar Q1 performance and eyes global growth opportunities

Inspire Medical Systems Inc delivered robust financial results in Q1 2023, driven by revenue growth and international expansion.
The company's strategic focus on innovation, customer engagement, and therapy adoption positions it well for future success.
Challenges in competition, operational efficiency, and market dynamics require careful navigation, but opportunities for growth and innovation abound.
Overall, Inspire's performance reflects a company poised for continued expansion and impact in the medical technology sector.

Inspire Medical Systems reports robust Q2 growth and eyes global expansion

Inspire Medical Systems delivered strong financial performance in Q2, with revenue growth and margin improvement.
The company's strategic focus on expanding globally, enhancing operational efficiency, and product innovation positions it for future success.
While facing challenges in managing expenses and market mix, Inspire Medical Systems is well-positioned to capitalize on growth opportunities.
Overall, the company's performance, strengths, and strategic initiatives indicate a positive outlook for future growth and market expansion.

Inspire Medical Systems achieves record patient milestone and revenue growth

Inspire Medical Systems reported strong performance in Q3 2023, with notable revenue growth and patient milestones.
Despite challenges with prior authorizations and EU MDR approval delays, the company remains focused on growth and stakeholder value.
Opportunities for expansion with payers and new programs signal a positive outlook for future growth and market reach.
Efforts to streamline processes, educate centers, and drive efficiencies position the company for continued success in the sleep apnea treatment market.

Inspire Medical Systems posts robust Q4 results, eyes global expansion

Inspire Medical Systems reported strong Q4 performance, focusing on growth, profitability, and patient outcomes.
Challenges include market competition, revenue declines in certain regions, and securing reimbursements.
Opportunities lie in expanding utilization rates, market growth in Europe and Asia, and collaborations for increased patient flow.

Inspire Medical Systems Inc reports robust Q1 performance and growth outlook

Inspire Medical Systems Inc's Q1 2024 performance reflects strong revenue growth, improved net loss metrics, and a positive outlook for profitability and revenue expansion in 2024.
The company's strengths lie in its patient-centric approach, innovative product pipeline, and strategic growth initiatives, while challenges include financial performance, competitive landscape, and market penetration.
Opportunities abound in expanding patient qualification, market awareness, and operational efficiency, positioning Inspire for sustained growth and market leadership in the healthcare sector.

Inspire Medical Systems reports strong Q2 performance and growth outlook

Inspire Medical Systems demonstrated robust financial performance, marked by revenue growth and improved profitability.
Strategic initiatives to enhance patient experience and expand market reach position the company for sustained growth.
While facing challenges related to rising expenses, the company's focus on operational efficiency and growth opportunities remains strong.

Inspire Medical Systems reports strong Q3 earnings and growth outlook

Inspire Medical Systems Inc demonstrated robust financial performance in Q3 2024, with revenue and net income showing significant growth.
Despite challenges like revenue headwinds in Q4, the company's focus on innovation and capacity expansion presents growth opportunities.
The upcoming launch of the Inspire V system and efforts to streamline patient access highlight Inspire's commitment to driving future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MINNEAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024.

Inspire Medical Systems, Inc. to Present at Jefferies London Healthcare Conference

Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the third quarter.

INSP Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts

Inspire Medical Systems, Inc. (NYSE:INSP ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Ezgi Yagci – Vice President-Investor Relations Tim Herbert – President and Chief Executive Officer Rick Buchholz – Chief Financial Officer Conference Call Participants Robbie Marcus – JPMorgan Danielle Antalffy – UBS Travis Steed – Bank of America Securities Adam Maeder – Piper Sandler David Rescott – Baird Michael Sarcone – Jefferies Richard Newitter – Truist Securities Larry Biegelsen – Wells Fargo Shagun Singh – RBC Kallum Titchmarsh – Morgan Stanley Jon Block – Stifel Anthony Petrone – Mizuho Americas Brett Fishbin – KeyBanc Capital Markets Chris Pasquale – Nephron Research Michael Polark – Wolfe Research Mike Kratky – Leerink Partners Suraj Kalia – Oppenheimer & Co Operator Good afternoon. My name is Dilem, and I'll be your conference operator today.

Inspire Medical Systems, Inc. (INSP) Q3 2024 Earnings Call Transcript

Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Inspire (INSP) Q3 Earnings

Inspire Medical Systems (INSP) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.29 per share a year ago.

Inspire Medical Systems (INSP) Q3 Earnings and Revenues Surpass Estimates

Inspire Reports Year-over-Year Revenue Growth of 33% and Earnings per Share of $0.60 in the Third Quarter Inspire Reports Year-over-Year Revenue Growth of 33% and Earnings per Share of $0.60 in the Third Quarter

Inspire Medical Systems, Inc. Announces Third Quarter 2024 Financial Results and Updates 2024 Outlook

Evaluate the expected performance of Inspire (INSP) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Seeking Clues to Inspire (INSP) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

MINNEAPOLIS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024.

Inspire Medical Systems, Inc. to Present at UBS Global Healthcare Conference

Omnicell

10X Genomics

Medical Systems, 10x Genomics and Omnicell have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell

Zacks Medical Info Systems industry stocks like Inspire Medical Systems, 10x Genomics and Omnicell are expected to gain from the GenAI wave.

3 Medical Info Systems Stocks to Gain From Healthcare Digitization

Inspire (INSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Inspire (INSP) Upgraded to Buy: What Does It Mean for the Stock?

MINNEAPOLIS, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2024 after the close of trading on Monday, November 4. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Inspire Medical Systems, Inc. to Report Third Quarter 2024 Financial Results on November 4, 2024

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Inspire Medical Systems (INSP) is a Strong Momentum Stock

Adient

Bio-Rad Laboratories

Community Healthcare Trust

Compass Minerals

CNH Industrial NV

Designer Brands

3D Systems

Dell Technologies

Dine Brands Global

Enhabit Inc

Fabrinet

Haverty Furniture Companies

MP Materials

Nu Skin Enterprises

Palantir Technologies

Parsons Corp

S&P Global

TEGNA

Western Alliance Bancorporation

Wolfspeed

Clear Secure

Zurn Water Solutions Corp

NEW YORK , Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance.

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

CareCloud Inc

Clover Health Investments

Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Clover Health Investments and CareCloud are expected to gain from the GenAI wave.

Buy These 3 Medical Info Systems Stocks to Capitalize on GenAI Boom

Inspire Medical Systems has shown impressive growth, become profitable and recently obtained FDA approval for a new device. The company's Inspire system treats sleep apnea with neurostimulation technology, achieving significant sales growth for years now. Trading at around 6 times sales, the company's strong performance, profitability, and growth potential make it an attractive investment.

Inspire Medical Systems: Inspired, With Improving Risk-Reward (Rating Upgrade)

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Inspire Medical Systems (INSP) is a Top Momentum Stock for the Long-Term

MINNEAPOLIS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024.

Inspire Medical Systems, Inc. to Present at Upcoming Investor Conferences

Inspire (INSP) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Inspire (INSP) Might be Well Poised for a Surge

Inspire Medical (INSP) reports strong second-quarter results, reflecting a 30% revenue increase. Its new technology and expanded U.S. presence promise growth and enhanced patient care.

Inspire Medical (INSP) Q2 Earnings Beat, Gross Margin Rises

Inspire Medical Systems, Inc. (INSP) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Inspire (INSP) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics

Inspire Medical Systems (INSP) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to loss of $0.41 per share a year ago.

Inspire Medical Systems (INSP) Tops Q2 Earnings Estimates

MINNEAPOLIS, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that its Board of Directors has authorized the repurchase of up to $150.0 million of the company's outstanding shares of common stock.

Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program

Inspire Reports Year-over-Year Revenue Growth of 30% in the Second Quarter Inspire Reports Year-over-Year Revenue Growth of 30% in the Second Quarter

News for Inspire Medical Systems Inc Stock (INSP)